288 related articles for article (PubMed ID: 37965333)
1. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
2. Identification of disulfidptosis-associated genes and characterization of immune cell infiltration in thyroid carcinoma.
Song S; Zhou J; Zhang L; Sun Y; Zhang Q; Tan Y; Zhou X; Yu J
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38836761
[TBL] [Abstract][Full Text] [Related]
3. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
4. A novel signature of the ligand and receptor genes associated with disulfidoptosis for prediction of prognosis, immunologic therapy responses in hepatocellular carcinoma.
Fu C; Cheng C; Zhang Y
Heliyon; 2023 Sep; 9(9):e19502. PubMed ID: 37662746
[TBL] [Abstract][Full Text] [Related]
5. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis Reveals Disulfidoptosis-Associated Genes as Promising Immunotherapeutic Targets: Insights Gained from Bulk Omics and Single-Cell Sequencing Validation.
Xu B; Li M; Weng N; Zhou C; Chen Y; Wei J; Fu L
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397869
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of single-cell and bulk RNA-sequencing data revealed disulfidptosis genes-based molecular subtypes and a prognostic signature in lung adenocarcinoma.
Wang H; Zhu X; Zhao F; Guo P; Li J; Du J; Shan G; Li Y; Li J
Aging (Albany NY); 2024 Feb; 16(3):2753-2773. PubMed ID: 38319721
[TBL] [Abstract][Full Text] [Related]
8. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
9. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
11. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
12. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
13. Integrative Analysis of Single-Cell and Bulk RNA Sequencing Reveals Prognostic Characteristics of Macrophage Polarization-Related Genes in Lung Adenocarcinoma.
Mi K; Zeng L; Chen Y; Yang S
Int J Gen Med; 2023; 16():5031-5050. PubMed ID: 37942473
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the potential of senescence-related genes in guiding clinical therapy of lung adenocarcinoma patients.
Liu C; Wei X
Funct Integr Genomics; 2023 May; 23(2):188. PubMed ID: 37246190
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
18. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
[TBL] [Abstract][Full Text] [Related]
19. Single-cell analysis reveals exosome-associated biomarkers for prognostic prediction and immunotherapy in lung adenocarcinoma.
Lin S; Zhou S; Han X; Yang Y; Zhou H; Chang X; Zhou Y; Ding Y; Lin H; Hu Q
Aging (Albany NY); 2023 Oct; 15(20):11508-11531. PubMed ID: 37878007
[TBL] [Abstract][Full Text] [Related]
20. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
